JP7271513B2 - 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬 - Google Patents

代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬 Download PDF

Info

Publication number
JP7271513B2
JP7271513B2 JP2020515081A JP2020515081A JP7271513B2 JP 7271513 B2 JP7271513 B2 JP 7271513B2 JP 2020515081 A JP2020515081 A JP 2020515081A JP 2020515081 A JP2020515081 A JP 2020515081A JP 7271513 B2 JP7271513 B2 JP 7271513B2
Authority
JP
Japan
Prior art keywords
azabicyclo
heptan
cyclopropyl
methoxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020515081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534275A (ja
JP2020534275A5 (https=
Inventor
ジャンファ チャオ，
Original Assignee
アルデリックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルデリックス， インコーポレイテッド filed Critical アルデリックス， インコーポレイテッド
Publication of JP2020534275A publication Critical patent/JP2020534275A/ja
Publication of JP2020534275A5 publication Critical patent/JP2020534275A5/ja
Priority to JP2023031187A priority Critical patent/JP2023065577A/ja
Application granted granted Critical
Publication of JP7271513B2 publication Critical patent/JP7271513B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020515081A 2017-09-14 2018-09-14 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬 Active JP7271513B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023031187A JP2023065577A (ja) 2017-09-14 2023-03-01 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558858P 2017-09-14 2017-09-14
US62/558,858 2017-09-14
PCT/US2018/051122 WO2019055808A1 (en) 2017-09-14 2018-09-14 HORMONE RECEPTOR MODULATORS FOR THE TREATMENT OF MUTAGENIC AND FIBROTIC METABOLIC CONDITIONS AND DISORDERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023031187A Division JP2023065577A (ja) 2017-09-14 2023-03-01 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬

Publications (3)

Publication Number Publication Date
JP2020534275A JP2020534275A (ja) 2020-11-26
JP2020534275A5 JP2020534275A5 (https=) 2021-10-21
JP7271513B2 true JP7271513B2 (ja) 2023-05-11

Family

ID=63714148

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020515081A Active JP7271513B2 (ja) 2017-09-14 2018-09-14 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬
JP2023031187A Pending JP2023065577A (ja) 2017-09-14 2023-03-01 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023031187A Pending JP2023065577A (ja) 2017-09-14 2023-03-01 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬

Country Status (6)

Country Link
US (1) US11753410B2 (https=)
EP (1) EP3681881B1 (https=)
JP (2) JP7271513B2 (https=)
CN (1) CN111655680B (https=)
MA (1) MA50242A (https=)
WO (1) WO2019055808A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55632A (fr) 2016-08-23 2022-02-16 Ardelyx Inc Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502389A (ja) 2009-08-19 2013-01-24 フェネックス ファーマシューティカルス アーゲー 新規のｆｘｒ（ｎｒ１ｈ４）結合性及び活性調節性化合物
JP2014500317A (ja) 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｆｘｒ調節のための組成物および方法
JP2014533258A (ja) 2011-11-15 2014-12-11 ゼンション・リミテッドＸｅｎｔｉｏｎ Ｌｉｍｉｔｅｄ カリウムチャネル阻害剤としてのチエノ［２，３−ｃ］ピラゾールの使用
WO2016097933A1 (en) 2014-12-18 2016-06-23 Novartis Ag Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228288B (it) 1989-01-09 1991-06-07 Zambon Spa Composti ad attivita' antiserotoninica
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
JP2014500319A (ja) 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
WO2012087520A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
MA55632A (fr) 2016-08-23 2022-02-16 Ardelyx Inc Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
KR102400183B1 (ko) 2017-07-06 2022-05-18 수안주 바이오파마슈티컬 컴퍼니 리미티드 Fxr 작용제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502389A (ja) 2009-08-19 2013-01-24 フェネックス ファーマシューティカルス アーゲー 新規のｆｘｒ（ｎｒ１ｈ４）結合性及び活性調節性化合物
JP2014500317A (ja) 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｆｘｒ調節のための組成物および方法
JP2014533258A (ja) 2011-11-15 2014-12-11 ゼンション・リミテッドＸｅｎｔｉｏｎ Ｌｉｍｉｔｅｄ カリウムチャネル阻害剤としてのチエノ［２，３−ｃ］ピラゾールの使用
WO2016097933A1 (en) 2014-12-18 2016-06-23 Novartis Ag Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases

Also Published As

Publication number Publication date
US11753410B2 (en) 2023-09-12
CN111655680A (zh) 2020-09-11
US20210380585A1 (en) 2021-12-09
EP3681881A1 (en) 2020-07-22
JP2020534275A (ja) 2020-11-26
EP3681881B1 (en) 2022-11-02
WO2019055808A1 (en) 2019-03-21
JP2023065577A (ja) 2023-05-12
MA50242A (fr) 2020-07-22
CN111655680B (zh) 2024-03-05

Similar Documents

Publication Publication Date Title
US11718619B2 (en) Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
CN108064223B (zh) 含羟基的fxr(nr1h4)调节化合物
JP2023065577A (ja) 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬
EP3704106A1 (en) Alkene compounds as farnesoid x receptor modulators
AU2018357878A1 (en) Spirocyclic compounds as farnesoid X receptor modulators
EP3704112B1 (en) Alkene spirocyclic compounds as farnesoid x receptor modulators
EP4069702A1 (en) Sstr5 antagonists
CN108341822A (zh) Fxr受体调节剂及其制备方法和应用
CN105189508B (zh) 作为janus激酶抑制剂的环烷基腈吡唑并吡啶酮
CN118201924A (zh) 杂环化合物及其用途
WO2023077070A1 (en) Rxfp1 agonists
RS66733B1 (sr) Inhibitori alfa v beta6 integrina
WO2015131773A1 (zh) 作为食欲素受体拮抗剂的哌啶衍生物
JP2016514709A (ja) ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン
CN119176808B (zh) 一种glp-1激动剂及其制备方法和应用
JP2025502899A (ja) Ｂｃｌ－２阻害薬
CN113677659B (zh) 可用作类法尼醇x受体调节剂的经取代的酰胺化合物
HK1251552B (zh) 含羟基的fxr(nr1h4)调节化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230404

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230426

R150 Certificate of patent or registration of utility model

Ref document number: 7271513

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250